X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cipla with Divis Laboratories - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs DIVIS LABORATORIES - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA DIVIS LABORATORIES CIPLA/
DIVIS LABORATORIES
 
P/E (TTM) x 44.2 31.3 141.3% View Chart
P/BV x 3.9 5.4 71.2% View Chart
Dividend Yield % 0.3 0.9 36.4%  

Financials

 CIPLA   DIVIS LABORATORIES
EQUITY SHARE DATA
    CIPLA
Mar-17
DIVIS LABORATORIES
Mar-17
CIPLA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs6221,222 50.9%   
Low Rs458784 58.5%   
Sales per share (Unadj.) Rs181.9153.1 118.8%  
Earnings per share (Unadj.) Rs12.939.9 32.2%  
Cash flow per share (Unadj.) Rs29.344.6 65.7%  
Dividends per share (Unadj.) Rs2.0010.00 20.0%  
Dividend yield (eoy) %0.41.0 37.1%  
Book value per share (Unadj.) Rs155.7201.8 77.1%  
Shares outstanding (eoy) m804.51265.47 303.1%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.06.6 45.3%   
Avg P/E ratio x42.025.1 167.1%  
P/CF ratio (eoy) x18.422.5 81.9%  
Price / Book Value ratio x3.55.0 69.8%  
Dividend payout %15.525.0 62.1%   
Avg Mkt Cap Rs m434,516266,266 163.2%   
No. of employees `00023.09.7 236.7%   
Total wages/salary Rs m26,3384,687 561.9%   
Avg. sales/employee Rs Th6,349.14,175.0 152.1%   
Avg. wages/employee Rs Th1,143.0481.5 237.4%   
Avg. net profit/employee Rs Th449.31,089.3 41.3%   
INCOME DATA
Net Sales Rs m146,30240,643 360.0%  
Other income Rs m2,287749 305.4%   
Total revenues Rs m148,58941,392 359.0%   
Gross profit Rs m24,75814,460 171.2%  
Depreciation Rs m13,2291,233 1,072.7%   
Interest Rs m1,59423 7,052.2%   
Profit before tax Rs m12,22213,953 87.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m-700-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,7983,349 53.7%   
Profit after tax Rs m10,35410,604 97.6%  
Gross profit margin %16.935.6 47.6%  
Effective tax rate %14.724.0 61.3%   
Net profit margin %7.126.1 27.1%  
BALANCE SHEET DATA
Current assets Rs m87,37040,105 217.9%   
Current liabilities Rs m33,0816,595 501.6%   
Net working cap to sales %37.182.5 45.0%  
Current ratio x2.66.1 43.4%  
Inventory Days Days87119 73.4%  
Debtors Days Days6281 77.2%  
Net fixed assets Rs m111,56719,995 558.0%   
Share capital Rs m1,609531 303.1%   
"Free" reserves Rs m123,64553,043 233.1%   
Net worth Rs m125,25453,574 233.8%   
Long term debt Rs m36,4540-   
Total assets Rs m209,53261,585 340.2%  
Interest coverage x8.7618.4 1.4%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.70.7 105.8%   
Return on assets %5.717.3 33.0%  
Return on equity %8.319.8 41.8%  
Return on capital %8.526.1 32.6%  
Exports to sales %34.20-   
Imports to sales %8.325.2 33.0%   
Exports (fob) Rs m50,050NA-   
Imports (cif) Rs m12,20310,259 118.9%   
Fx inflow Rs m51,06635,384 144.3%   
Fx outflow Rs m17,67810,399 170.0%   
Net fx Rs m33,38824,985 133.6%   
CASH FLOW
From Operations Rs m23,82411,493 207.3%  
From Investments Rs m-13,127-11,372 115.4%  
From Financial Activity Rs m-13,239-93 14,219.7%  
Net Cashflow Rs m-2,47828 -8,725.4%  

Share Holding

Indian Promoters % 16.0 52.0 30.8%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 11.8 103.4%  
FIIs % 23.7 19.0 124.7%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 17.2 152.3%  
Shareholders   161,166 31,796 506.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   PFIZER  ABBOTT INDIA  PANACEA BIOTECH  DR. REDDYS LAB  GSK PHARMA  

Compare CIPLA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Share Markets Trade Flat; TCS Surges 3.5%(01:30 pm)

Indian share markets continued to trade on a flat note in the noon session. Gains are largely seen in software stocks, bank stocks and capital goods' stocks.

Related Views on News

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Is it Wise to Ignore Bitcoins?(The 5 Minute Wrapup)

Jan 4, 2018

While investing in bitcoins, it would make sense to treat it as another asset class and decide accordingly.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Jan 16, 2018 03:33 PM

TRACK CIPLA

CIPLA - PANACEA BIOTECH COMPARISON

COMPARE CIPLA WITH

MARKET STATS